Findings from a large US registry study to assess the real-world utility of a non-invasive gene expression test designed to rule out primary cutaneous melanoma

Main Article Content

Brook Brouha
Laura K Ferris
Maral K Skelsey
Gary Peck
Zuxu Yao
Burkhard Jansen

Keywords

melanoma, cutaneous melanoma, gene expression test

Abstract

Abstract not available.

References

1. Gerami P et al. Development and validation of a non-invasive 2-gene
molecular assay for cutaneous melanoma. J Am Acad Dermatol.
2017;76(1)114-120.e2

2. Ferris L et al. Real-world performance and utility of a non-invasive
gene expression assay to evaluate melanoma risk in pigmented
lesions. Mel Res. 2018; 28(5):478-482.

3. Hornberger J and Siegel D. Economic analysis of a non-invasive
molecular pathologic assay for pigmented skin lesions. JAMA
Dermatol. 2018; 154(9)1-8.

4. Ferris L et al. Impact on clinical practice of a non-invasive gene
expression melanoma rule-out test: 12 month follow-up of negative
test results and utility data from a large US registry study. Dermatol
Online J. 2019; 25(5):1-8.